Monogram Biosciences, Inc. (Nasdaq: MGRM) announced today that Medi-Cal has expanded its coverage of HIV resistance testing to include treatment naive patients as well as patients failing therapy. While genotypic resistance testing has traditionally been covered for patients who fail anti-HIV treatment, the expanded coverage allows for baseline genotypic resistance testing for all HIV infected patients, including those who are newly diagnosed and who are treatment naïve. Medi-Cal is California's Medicaid program, which provides medical service coverage for low-income and disabled individuals.
This expanded coverage only adds to the already terrific news. Set your countdown timers. Wed June 20th the FDA is scheduled to approve Maraviroc!
http://ir.monogrambio.com/releasedetail.cfm?ReleaseID=249550....
$11.04 (06/18/07)
